Outset Medical Q3 revenue rises 3%, lowers 2025 guidance

Outset Medical

10/11/2025 21:35

Overview

Outset Medical Q3 revenue grows 3% to $29.4 mln, driven by Tablo console sales

Company revises 2025 revenue guidance to $115-120 mln, down from $122-126 mln

Operating expenses decline nearly 20% yr/yr, aiding path to profitability

Outlook

Outset revises 2025 revenue guidance to $115 mln-$120 mln from $122 mln-$126 mln

Company maintains non-GAAP gross margin guidance in high-30% range

Outset expects to use less than $50 mln cash in 2025, down from over $100 mln in 2024

Result Drivers

TABLO CONSOLE SALES - 8% increase in Tablo console revenue drove Q3 revenue growth

ORDER TIMING - Consumable revenue was dampened by order timing

COST REDUCTIONS - Operating expenses declined nearly 20%, aiding path to profitability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$17.84 mln
Q3 Gross Margin
39.40%
Q3 Basic EPS
-$1
Q3 Gross Profit
$11.59 mln
Q3 Operating Expenses
$27.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Outset Medical Inc is $23.50, about 48.7% above its November 7 closing price of $12.06

Press Release: ID:nGNX6CcsFz

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)